

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10581613	
	Filing Date		2004-06-12	
	First Named Inventor	Jody Berry et al		
	Art Unit			
	Examiner Name			
	Attorney Docket Number		85084-802	

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	2004/092332	WO		2004-10-28	CIPHERGEN BIOSYSTEMS, INC.		<input type="checkbox"/>
	2	2004/092360	WO		2004-10-28	CHIRON CORPORATION		<input type="checkbox"/>
	3	2005/010034	WO		2005-02-03	NATIONAL INSTITUTES OF HEALTH		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10581613
Filing Date	2004-06-12
First Named Inventor	Jody Berry et al
Art Unit	
Examiner Name	
Attorney Docket Number	85084-802

4	2005/027847	WO		2004-03-31	ALEXION PHARMACEUTICALS INC.	<input type="checkbox"/>
---	-------------	----	--	------------	------------------------------------	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

**NON-PATENT LITERATURE DOCUMENTS**

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	Gubbins MJ et al "Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus" MOLECULAR IMMUNOLOGY vol 42, 9 August 2004 pages 125-136	<input type="checkbox"/>
	2	Berry JD et al "Development and characterization of neutralising monoclonal antibody to the SARS-coronavirus" JOURNAL OF VIROLOGICAL METHODS vol 120 no. 1. 1 September 2004 pages 87-96	<input type="checkbox"/>
	3	SUI J. et al "Potent neutralization of Severe Acute Respiratory Syndrome (SARS) coronavirus by a human MAb to S1 protein that blocks receptor association" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES vol 101, No. 8 February 24, 2004 pages 2536-2541	<input type="checkbox"/>
	4	ZHOU et al "An exposed domain in the Severe Acute Respiratory Syndrome coronavirus spike protein induces neutralizing antibodies" JOURNAL OF VIROLOGY Vol 78 No. 13 July 2004 pages 7217-7226	<input type="checkbox"/>
	5	CHE XY et al "Rapid and efficient preparation of monoclonal antibodies against SARS associated coronavirus nucleocapsid protein by immunizing mice" DI YI JUN YI DA XUE XUE BAO Vol 23 no 7 July 2003 pages 640-642	<input type="checkbox"/>
	6	HE Y ET AL "Receptor binding domain of SARS CoV spike protein induces highly potent neutralizing antibodies: implicated for developing subunit vaccine" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS vol 324, 2 October 2004 pages 773-781	<input type="checkbox"/>
	7	XIONG S et al "immunogenicity of SARS inactivated vaccine in BALB/c mice "IMMUNOLOGY LETTERS vol 95, 1 August 2004 pages 139-143	<input type="checkbox"/>
	8	HOLMES K: SARS coronavirus: a new challenge for prevention and therapy: THE JOURNAL OF CLINICAL INVESTIGATION VOL 111, 1 June 2003 pages 1605-1609	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10581613
Filing Date		2004-06-12
First Named Inventor	Jody Berry et al	
Art Unit		
Examiner Name		
Attorney Docket Number	85084-802	

9	ROTA PA ET AL "Characterization of a novel coronavirus associat ed with severe acute respiratory syndrome" "SCIENCE VOL 300 30 may 2003 pages 1394-1399 2003	<input type="checkbox"/>
---	--	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button **Add**

**EXAMINER SIGNATURE**

Examiner Signature	/Mary Mosher/	Date Considered	07/08/2009
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.